Cargando…

Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy

mTOR inhibitors have demonstrated remarkable anti-tumor activity in experimental models, mainly by reducing cancer cell growth and tumor angiogenesis. Their use in cancer patients as monotherapy has, however, generated only limited benefits, increasing median overall survival by only a few months. L...

Descripción completa

Detalles Bibliográficos
Autores principales:	Faes, Seraina, Santoro, Tania, Demartines, Nicolas, Dormond, Olivier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704170/ https://www.ncbi.nlm.nih.gov/pubmed/29104248 http://dx.doi.org/10.3390/cancers9110152

Ejemplares similares

Acidic pH reduces VEGF-mediated endothelial cell responses by downregulation of VEGFR-2; relevance for anti-angiogenic therapies
por: Faes, Seraina, et al.
Publicado: (2016)

Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors
por: Faes, Seraina, et al.
Publicado: (2016)

Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives
por: Faes, Seraina, et al.
Publicado: (2021)

Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity
por: Faes, Seraina, et al.
Publicado: (2017)

Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives
por: Dufour, Marc, et al.
Publicado: (2011)

Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells
por: Blaser, Benjamin, et al.
Publicado: (2012)

Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer
por: Uldry, Emilie, et al.
Publicado: (2017)

mTOR and Tumor Cachexia
por: Duval, Adrian P., et al.
Publicado: (2018)

Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
por: Roulin, Didier, et al.
Publicado: (2011)

Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors
por: Faes, Seraina, et al.
Publicado: (2016)

mTOR in Human Diseases
por: Dormond, Olivier
Publicado: (2019)

Combining mTOR Inhibitors and T Cell-Based Immunotherapies in Cancer Treatment
por: el Hage, Alexandre, et al.
Publicado: (2021)

PI3K and AKT: Unfaithful Partners in Cancer
por: Faes, Seraina, et al.
Publicado: (2015)

Methylnaltrexone Potentiates the Anti-Angiogenic Effects of mTOR Inhibitors
por: Singleton, Patrick A, et al.
Publicado: (2010)

Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using (111)In-bevacizumab
por: Patel, Neel, et al.
Publicado: (2017)

Cytokine clearance in serum and peritoneal fluid of patients undergoing damage control surgery with abdominal negative pressure therapy for abdominal sepsis
por: Faes, Seraina, et al.
Publicado: (2020)

Rate of stoma formation following damage-control surgery for severe intra-abdominal sepsis: a single-centre consecutive case series
por: Faes, Seraina, et al.
Publicado: (2021)

Elective Surgery for Diverticulitis in Swiss Hospitals
por: Faes, Seraina, et al.
Publicado: (2021)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Is liquid biopsy the future commutator of decision-making in liver transplantation for hepatocellular carcinoma?
por: Gonvers, Stéphanie, et al.
Publicado: (2022)

Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling
por: Allen, Elizabeth, et al.
Publicado: (2016)

Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
por: Roulin, Didier, et al.
Publicado: (2010)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Inhibitors of mTOR in aging and cancer
por: Zhavoronkov, Alexander
Publicado: (2015)

Gerosuppression by pan-mTOR inhibitors
por: Leontieva, Olga V., et al.
Publicado: (2016)

mTOR inhibitors in cancer therapy
por: Xie, Jianling, et al.
Publicado: (2016)

mTor Inhibitors for the Treatment of Endometriosis
por: Barra, Fabio, et al.
Publicado: (2018)

Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021)

Overview of Research into mTOR Inhibitors
por: Mao, Beibei, et al.
Publicado: (2022)

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer
por: Bhin, Jinhyuk, et al.
Publicado: (2023)

Modulation of mTOR Signalling Triggers the Formation of Stem Cell-like Memory T Cells
por: Scholz, Godehard, et al.
Publicado: (2016)

Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016)

The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication
por: Labgaa, Ismail, et al.
Publicado: (2021)

Basic Science with Preclinical Models to Investigate and Develop Liquid Biopsy: What Are the Available Data and Is It a Fruitful Approach?
por: Cena, Benedetta, et al.
Publicado: (2022)

Deciphering Combinations of PI3K/AKT/mTOR Pathway Drugs Augmenting Anti-Angiogenic Efficacy In Vivo
por: Sasore, Temitope, et al.
Publicado: (2014)

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

Predicted mechanisms of resistance to mTOR inhibitors
por: Kurmasheva, R T, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_t04hl9dplpjc7t9c7tpmn6ltgl